AKTX

Akari Therapeutics, Plc [AKTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

AKTX Stock Summary

Top 10 Correlated Stocks

AKTX

In the News

AKTX Financial details

Company Rating
-
Market Cap
8.01M
Income
-6.44K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-26.86
Forward P/E
-
PEG
11.09
P/S
-
P/B
104.6
P/C
-
P/FCF
-0.71
Quick Ratio
1.35
Current Ratio
1.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.69
EPS next Y
-
EPS next Q
-
EPS this Y
-8.52%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-190%
ROC
-12.89%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.1-5.5
52W High
-75.3%
52W Low
+23.5%
RSI
55
Rel Volume
0.19
Avg Volume
12.26K
Volume
2.29K
Perf Week
15.42%
Perf Month
37.37%
Perf Quarter
-48.54%
Perf Half Y
-42.82%
-
-
-
-
Beta
0.965
-
-
Volatility
0.07%, 0.15%
Prev Close
-3.52%
Price
1.235
Change
16.51%

Something similar

Top by Market Cap
DHR-PB
APC.DE
ABEC.DE
AMZ.DE
VTI
Same Sector
PETVW
ABC
CTEC.L
PIII
ZIM.DE
Top Correlated Stocks
LITM
002278.SZ
HROW
603776.SS
WBI.L
Similar Market Cap
WATT
SYM.L
SYNB
ATIF
MNM

Company Profile

Healthcare Biotechnology
  • Volume Average 12.26K
  • Market Capitalization 8.01M
  • Employee 9
  • CEO Ms. Rachelle Suzanne Jacques
  • Headquarters London,GB
  • IPO Date 2014-01-06
  • Website https://www.akaritx.com

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.